Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
November 08, 2018BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Asterias Stockholders to Receive 0.71 Shares of BioTime for Each Share of Asterias Biotherapeutics ALAMEDA, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--Nov. 8, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American: AST), today ann... 
Printer Friendly Version
November 08, 2018BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRegen® Data Presented at 2018 American Academy of Ophthalmology Annual Meeting Date Set for Distribution of AgeX Therapeutics Shares to BioTime Stockholders ALAM... 
Printer Friendly Version
November 06, 2018BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call
Call moved to 5:30 a.m. PT / 8:30 a.m. ET on November 8th, 2018 ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 6, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously announced conference call to discuss its third quarter 2018 financial and operating results. BioTime management will be hosting the call on Thursd... 
Printer Friendly Version
November 05, 2018BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
Sale of AgeX subsidiary will help support development of BioTime’s core programs Balance owed for remaining portion of transaction totals $21.6 million ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 5, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment of $10.8 million pursua... 
Printer Friendly Version
October 30, 2018BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 30, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8th, 2018, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, November 8th, 2018, at 4:30 p.m... 
Printer Friendly Version
October 29, 2018BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina and Decrease of Drusen Density Observed in Some Patients ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 29, 2018-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, ... 
Printer Friendly Version
October 25, 2018BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares
BioTime Shareholders To Receive One Share of AgeX Common Stock for Every 10 Shares of BioTime Common Stock ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for and distribution date for the distribution of AgeX Therapeutics (“AgeX”) shares owned by BioTime on a ... 
Printer Friendly Version
October 22, 2018BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
Abstract Selected to be Highlighted by the American Academy of Ophthalmology Organization Committee ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development ... 
Printer Friendly Version
September 27, 2018BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 27, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will present at the upcoming MicroCap and Ladenburg Thalmann conferences. The MicroCap Conference will take place on October 1, 2018 at the Essex House in New York. The presentation will take place at 10:30am ... 
Printer Friendly Version
September 25, 2018BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Francois Binette, Senior Vice President and BioTime’s Head of Global Development, will participate in a panel discussion at the National Eye Institute Conference at 10:15am ET/7:15am PT on Tuesday, September 25, 2018 in Bethesda, Maryland. This conference is brin... 
Printer Friendly Version
September 21, 2018BioTime Warrants to Expire on October 1, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 21, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, is advising the holders of its publicly traded warrants (NYSE American: BTX.WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 1, 2018 (the “Expiration Date”). A warrant holder can obtain information on exercising the warrants by ... 
Printer Friendly Version
September 18, 2018BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Former Co-CEO Adi Mohanty to Aid in Transition and Continue to Serve on the Boards of Asterias and OncoCyte Former Co-CEO Michael West to Focus on AgeX CEO Responsibilities ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 18, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the Board of Directors has implemented a new leadership structure under w... 
Printer Friendly Version
September 17, 2018BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
Regulatory Approvals In-Process; New Record Date to be Set Shortly ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 17, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record date for the distribution of AgeX Therapeutics, Inc. (“AgeX”) shares to BioTime shareholders. The ratio of one share of AgeX common stock for every 10 share... 
Printer Friendly Version
September 04, 2018BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
Proceeds provide sufficient capital to fund BioTime through major milestones for current programs, including Renevia® and OpRegen® key data and decisions BioTime and its shareholders participate in potential Juvenescence upside after conversion of note upon Juvenescence IPO BioTime and its shareholders continue to participate in potential AgeX upside from retained share ownership and continuation of rights ... 
Printer Friendly Version
August 28, 2018BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences
Adi Mohanty to participate in panel discussion at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to host investor one-on-one meetings at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to host investor one-on-one meetings at the 20th Annual Rodman & Renshaw Global Investment Conference ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28... 
Printer Friendly Version
August 16, 2018BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 16, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will be presenting a poster at the Military Health System Research Symposium (MHSRS) from August 20-23, 2018 in Kissimmee, Florida. The poster presentation is titled, “Next generation disease modifying viscosupplementation to delay or prevent invasive surgery in ... 
Printer Friendly Version
August 02, 2018BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
BioTime to receive $43 million from Juvenescence BioTime shareholders to receive one share of AgeX common stock for every 10 shares of BioTime common stock held BioTime clinical programs including OpRegen® for dry-AMD and Renevia® for volume enhancement are on track Conference call and webcast today at 1:30pm PT/4:30pm ET ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 2, 2018-- BioTime,... 
Printer Friendly Version
August 02, 2018BioTime to Receive $43 Million From Juvenescence
BioTime to receive $21.6 million in cash and $21.6 million in a convertible/redeemable note for 14.4 million shares of AgeX Therapeutics Creates alignment between AgeX Therapeutics and Juvenescence Limited to potentially become leader in the field of aging ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 2, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, ... 
Printer Friendly Version
August 02, 2018BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 2, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported that Gordon H. Sasaki, M.D., F.A.C.S., has initiated his independent investigator-initiated study of Premvia™ combined with the patient’s own fat for volume augmentation of the hand. Dr. Sasaki is a board-certified plastic surgeon serving Los Angeles and Pasadena, Calif... 
Printer Friendly Version
August 01, 2018BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares
BioTime shareholders will receive one share of AgeX common stock for every 10 shares of BioTime common stock held ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 1, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the distribution ratio for the distribution of AgeX Therapeutics shares owned by BioTime on a pro-rata basis to eligible... 
Printer Friendly Version
July 25, 2018Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
Presentation to include data from new as well as previously treated patients ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation a... 
Printer Friendly Version
July 23, 2018BioTime to Announce Second Quarter 2018 Results on August 2, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 23, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, August 2, 2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to d... 
Printer Friendly Version
July 10, 2018BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares
- Distribution to BioTime shareholders as of the Record Date on pro rata basis - - Distribution Ratio and Distribution Date to be announced at a later date - ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 10, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for the distribution of AgeX Therapeutics (“Age... 
Printer Friendly Version
June 29, 2018BioTime Awarded Grant From the NIH
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 29, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). This award constitutes the second-year funding of a $1.6 million SBIR grant to advance BioTime’s innovative, next generation retinal re... 
Printer Friendly Version
June 25, 2018BioTime Licenses GMP Cell Line to Goliver Therapeutics
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 25, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver Therapeutics, a France-based company focused on addressing liver diseases with regenerative technologies. “We are excited to help enable the team at Goliver to further their mission to treat liver diseases with differentiated cells c... 
Printer Friendly Version
June 08, 2018BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
- Draft registration statement filed on Form 10 with the U.S. Securities and Exchange Commission - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 8, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission (the “SEC”). The draft registration statement relates to the pro... 
Printer Friendly Version
May 30, 2018BioTime to Present at the 8th Annual LD Micro Invitational
ALAMEDA, Calif.--(BUSINESS WIRE)--May 30, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the 8th Annual LD Micro Invitational Conference on Monday, June 4, 2018 at 1:30pm PT, at the Luxe Sunset Bel Air Hotel in Los Angeles, California. Mr. Skibsted will also be meeting with investors... 
Printer Friendly Version
May 29, 2018BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
ALAMEDA, Calif.--(BUSINESS WIRE)--May 29, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million... 
Printer Friendly Version
May 24, 2018BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
Diana V. Do, MD, Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine David Telander, MD, PhD at The Retinal Consultants Medical Group serving northern California ALAMEDA, Calif.--(BUSINESS WIRE)--May 24, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/II... 
Printer Friendly Version
May 10, 2018BioTime Reports First Quarter Results and Recent Corporate Accomplishments
Renevia® CE Mark application successfully submitted for European approval OpRegen® cohort 4 initiated in better-vision patients OpRegen® data slides, conference call and webcast today at 1:30pm PT/4:30pm ET ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial re... 
Printer Friendly Version
May 01, 2018BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
Signs of structural improvement in the retina Signs of a reduction and change in drusen material Signs of engraftment and cell survival have been maintained for over 2 years in some patients ALAMEDA, Calif.--(BUSINESS WIRE)--May 1, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of it... 
Printer Friendly Version
April 26, 2018BioTime to Announce First Quarter 2018 Results on May 10, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, May 10, 2018, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to disc... 
Printer Friendly Version
April 16, 2018Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
OpRegen® is in a Phase I/IIa clinical trial for dry-AMD Retinal Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for R... 
Printer Friendly Version
April 09, 2018Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 9, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy Innovation Summit. The presentation will take place on April 27th, 2018 from 8:15am – 8:30am local time, in Honolulu, Hawaii. The OpRegen® data will be presen... 
Printer Friendly Version
March 27, 2018BioTime Announces Cash Sale of Ascendance Biotechnology
BioTime subsidiary, AgeX, to receive up to $3.5 million in cash ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 27, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc. BioTime’s subsidiary, AgeX Therapeutics, Inc. (AgeX), owned a minority stake in Ascendance at the time of the acquisition. AgeX will receive up to $3... 
Printer Friendly Version
March 15, 2018BioTime Reports Fourth Quarter and Fiscal 2017 Results
Renevia® CE Mark application submitted for European approval OpRegen® receives DSMB approval to proceed to cohort 4 OpRegen® cohort 4 will include better vision patients and an array of additional functional assessments ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 15, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial ... 
Printer Friendly Version
March 13, 2018BioTime Submits CE Mark Application for European Approval of Renevia®
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market Renevia® in Europe. BioTime anticipates CE Mark approval in the second half of 2018. “Submission of the CE Mark application establishes an important milestone for BioTime and we a... 
Printer Friendly Version
March 07, 2018BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
Continued safety from cohorts 1, 2 and 3 included in assessment by independent DSMB Cohort 4 will focus on earlier stage dry-AMD patients Additional functional data assessments are included in Cohort 4 ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the indep... 
Printer Friendly Version
March 05, 2018BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 5, 2018-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2017 financial and operating results on Thursday, March 15, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, Mar... 
Printer Friendly Version
February 28, 2018BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 28, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the Raymond James 39th Annual Institutional Investor Conference on Wednesday, March 7, 2018 at 10:25am ET, at the J.W. Marriott Grande Lakes Hotel. ... 
Printer Friendly Version
February 26, 2018BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
20 years of biopharma clinical development and medical affairs experience Prior Clinical lead for Tysabri at Elan Pharmaceuticals Prior Medical lead for Questcor ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 26, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appoin... 
Printer Friendly Version
February 22, 2018BioTime Appoints Cavan Redmond to Its Board of Directors
Former CEO of WebMD, former General Manager of Wyeth Biopharma and Group President of Pfizer 30 Years of Executive Management and Corporate Strategy Experience in Biopharma ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redm... 
Printer Friendly Version
February 15, 2018Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
OpRegen® is in a Phase I/IIa clinical trial for dry-AMD Vision Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 15, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be presented at the upcoming Association f... 
Printer Friendly Version
February 07, 2018BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of BioTime, will participate in the BIO CEO and Investor Conference, on February 12th and 13th 2018, at the New York Marriott Marquis. The BIO CEO and Investor Conference is one ... 
Printer Friendly Version
January 29, 2018Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 29, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal trial of Renevia® in Europe will be presented at the International Master Course on Aging Science (IMCAS) conference on February 3, 2018. The Renevia® data will be presented by primar... 
Printer Friendly Version
January 23, 2018BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 23, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Noble Capital Markets 14th Annual Investor Conference on Monday, January 29, 2018 at 4:00pm ET, at the W Hotel Fort Lauderdale. A webcast of ... 
Printer Friendly Version
January 22, 2018BioTime Announces Clinical and Corporate Milestone Targets for 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets. BioTime will continue to focus on the core pillars of its stated strategy of Clinical Progress, Simplification and Unlocking Value for BioTime Shareholders. ... 
Printer Friendly Version
January 17, 2018BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
BioTime expands and strengthens patent estate covering OpRegen® through 2031 Expanded and strengthened patent coverage of pluripotent cell technology ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 17, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over th... 
Printer Friendly Version